期刊文献+

替代指标和中间指标及其在中医药疗效评价研究中应用价值的思考 被引量:56

Thinking on Surrogate Outcomes,Intermediary Outcomes and Their Application in TCM Clinical Efficacy Evaluation
下载PDF
导出
摘要 论述了替代指标、中间指标的概念,其与主要结局指标之间的关系以及替代指标在临床疗效评价研究中的应用条件,同时讨论了在中医药疗效评价研究中如何选择替代指标和中间指标的问题。基于中医药整体性特点,使用单一替代指标难以全面而客观地反应中医药的疗效,合理地选择重要临床症状、若干症状的组合、病人的主观感觉、对于治疗的总体满意度等中间指标和生存质量,将有助于客观评价中医药干预措施的效能。 In this paper, the concepts of surrogate outcomes and intermediary outcomes, their correlation with the primary outcome, how to select surrogate outcomes and intermediary outcomes and the particular requirements for using surrogate outcomes in assessing TCM clinical efficacy were discussed and described. It is difficult to evaluate clinical efficacy objectively and thoroughly by means of a single surrogate outcome for reason of the global characteristics of TCM, therefore, to rationally select such intermediary outcomes as important clinical symptoms, combination of several syndromes, patients' subject feeling, patients' satisfaction for treatment and quality of life, should be beneficial for objectively evaluating the efficacy of TCM intervention approaches.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2005年第7期585-590,共6页 Chinese Journal of Integrated Traditional and Western Medicine
基金 广东省科技厅项目(No.2KM05801S)
关键词 替代指标 中间指标 中医药 疗效评价 surrogate outcomes intermediary outcomes traditional Chinese medicine clinical outcome assessment
  • 相关文献

参考文献20

  • 1郭新峰,赖世隆,梁伟雄.中医药临床疗效评价中结局指标的选择与应用[J].广州中医药大学学报,2002,19(4):251-255. 被引量:147
  • 2Oliver MF, Heady JA, Morris JN, et al. for the Committee of Principal Investigators. WHO cooperative trial of primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984 ;2:600-604. 被引量:1
  • 3Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259. 被引量:1
  • 4Echt DS, Leibson PR, Mitchel LB, et al. Cardiac arrhythmia suppression trial. N Engl J Med. 1989 ;321:406. 被引量:1
  • 5黄峻,王文主编..心脑血管疾病大型临床试验[M].南京:江苏科学技术出版社,1998:919.
  • 6Fleming TR, De Mets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med, 1996; 125 (7):605-613. 被引量:1
  • 7Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trial results.Part A: How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999; 282 (8): 771-778. 被引量:1
  • 8李瑞杰.心血管病危险因素治疗的替代终点,健康预后和药物批准过程[J].美国医学会杂志(中文版),2000,19(4):198-201. 被引量:3
  • 9Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA.1999 ;282(8): 786-790. 被引量:1
  • 10何春黎.医学文献使用指标:XIX临床试验结果的应用A.怎样使用那些只?…[J].美国医学会杂志(中文版),2000,19(4):192-197. 被引量:1

二级参考文献11

共引文献238

同被引文献1013

引证文献56

二级引证文献579

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部